348 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 7 of 7
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself or in combination with pembrolizumab, SOC chemotherapy, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
In this research study, an investigational medication named ACR-368 (also known as prexasertib) is being tested for the treatment of ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Cancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the disease from returning for…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The main purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans. Cancers include bladder cancer, breast cancer, colon and rectal…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE